Abstract

Possible smallpox reemergence drives research for third-generation vaccines that effectively neutralize variola virus. A comparison of neutralization assays using different substrates, variola and vaccinia (Dryvax and modified vaccinia Ankara [MVA]), showed significantly different 90% neutralization titers; Dryvax underestimated while MVA overestimated variola neutralization. Third-generation vaccines may rely upon neutralization as a correlate of protection.

Links

PMC Free PDF

PMC Free Full Text

Publisher Full Text

Authors

Hughes CM, Newman FK, Davidson WB, Olson VA, Smith SK, Holman RC, Yan L, Frey SE, Belshe RB, Karem KL, Damon IK

Institution

National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Christine.Hughes@cdc.hhs.gov

Source

Clinical and vaccine immunology : CVI 19:7 2012 Jul pg 1116-8

MeSH

Antibodies, Neutralizing
Antibodies, Viral
Humans
Neutralization Tests
Smallpox Vaccine
Vaccinia virus
Variola virus

Pub Type(s)

Comparative Study
Evaluation Studies
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

22593237